Purpose: The interleukin-13 receptor a2 (IL-13Ra2) is expressed by a variety of human malignant cells. Here, we have examined the constitutive surface expression and the epigenetic regulation of IL-13Ra2 by human mesothelioma. We have also investigated the therapeutic effect of the DNA methylation inhibitor 5-aza-2 0 -deoxycytidine (5-aza-dC) and anti-IL-13Ra2 monoclonal antibody on mesothelioma xenografts.Experimental Design: Cell surface expression of IL-13Ra2 by various lung carcinomas was analyzed using flow cytometry. Therapeutic effects of anti-IL-13Ra2 and 5-aza-dC were investigated using antibodydependent cellular cytotoxicity and proliferation assays and by monitoring the survival of mesotheliomabearing mice.Results: We found that human malignant mesotheliomas expressed surface IL-13Ra2 on their surface and that it was upregulated by treatment with 5-aza-dC. This augmented expression of IL-13Ra2 resulted in growth inhibition of the mesothelioma cells when cocultured with anti-IL-13Ra2 and effector cells, such as splenocytes and peritoneal exudate cells. The growth inhibition of mesothelioma cells was mediated by IFN-g that was only detected in the supernatant when effector cells were exposed to 5-aza-dC-treated tumors in the presence of anti-IL-13Ra2. Compared with the control or either regimen alone, in vivo administration of anti-IL-13Ra2 in combination with 5-aza-dC significantly prolonged the survival of mice with mesothelioma xenografts.Conclusions: These observations indicate a promising role for IL-13Ra2 as a target for antibody treatment in malignant mesothelioma, and, in combination with epigenetic regulation by a DNA methylation inhibitor, suggest the potential for a novel strategy to enhance therapeutic potency.
Purpose: Interleukin-13 receptor β2 (IL13Rα2) is known as a cancer antigen and high expression of this receptor is found in various human cancers, such as glioma, renal cell carcinoma and prostate carcinoma. Immunotoxin or cytotoxin therapy for malignant glioma targeting IL13Rα2 has already been investigated in preclinical and clinical trials. Here, we have examined the constitutive surface expression and the epigenetic regulation of IL13Rα2 by human mesothelioma. We have also investigated the therapeutic effect of the DNA methylation inhibitor, 5-aza-2′-deoxycytidine (5-aza-dC), and anti-IL13Rα2 monoclonal antibody on mesothelioma xenografts. Experimental Design: Cell surface expression of IL13Rα2 by various lung carcinomas was analyzed using flow cytometry. Therapeutic effects of anti-IL13Rα2 and 5-aza-dC were investigated using antibody-dependent cellular cytotoxicity and proliferation assays, and by monitoring the survival of mesothelioma-bearing mice. Results: We found that human malignant mesotheliomas expressed surface IL13Rα2 on their surface and that it was up-regulated by treatment with 5-aza-dC. This augmented expression of IL13Rα2 resulted in growth inhibition of the mesothelioma cells when co-cultured with anti-IL13Rα2 and effector cells, such as splenocytes and peritoneal exudate cells. The growth inhibition of mesothelioma cells was mediated by interferon-α that was only detected in the supernatant when effector cells were exposed to 5-aza-dC-treated tumors in the presence of anti-IL13Rα2. Compared with the control or either regimen alone, in vivo administration of anti-IL13Rα2 in combination with 5-aza-dC significantly prolonged the survival of mice with mesothelioma xenografts. Conclusion: These observations indicate a promising role for IL13Rα2 as a target for antibody treatment in malignant mesothelioma, and, in combination with epigenetic regulation by a DNA methylation inhibitor, suggest the potential for a novel strategy to enhance therapeutic potency. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1555. doi:1538-7445.AM2012-1555
Anatomicalvariationsofmesentericarteriesareuncommon,andamongthose,duplicationofthesuperiormesentericartery(SMA)hasseldombeenreported.WereportararecaseofSMAduplicationand incompleteintestinalmalrotationina57-year-oldJapanesemanwithearlyrectalcancer(15mminsize, 0-IIa+IIctype)diagnosedinacolorectalcancerscreening,togetherwithreviewoftheliterature. Preoperative contrast enhanced computed tomography revealed two SMAs, though there were no distantandlymphnodemetastases.ThefirstSMAhadarisenfromtheabdominalaortaatitsusualdistancefromtheceliacarteryandgavebranchestothejejunum.ThesecondSMAhadoriginatedfromthe inferiormesentericartery(IMA),ranupward,andthenturnedcounter-clockwiseanddownwardgiving risetobranchestotherightcolonandtheileum.Itappearedthatthe1 st SMAmightfeedthejejunum andthe2 nd SMA,theileumandtherightcolon.Incompleteintestinalmalrotationof180degreeswasalso visualized. LaparoscopicanteriorresectionpreservingtherootofIMA,the2 nd SMAandtheleftcolicarterywas performed,andthepostoperativecoursewasuneventful.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.